Accelerated fractionation head and neck intensity‐modulated radiation therapy and concurrent chemotherapy in the community setting: Safety and efficacy considerations
Identifieur interne : 003681 ( Istex/Corpus ); précédent : 003680; suivant : 003682Accelerated fractionation head and neck intensity‐modulated radiation therapy and concurrent chemotherapy in the community setting: Safety and efficacy considerations
Auteurs : Alan T. Monroe ; James A. Young ; Jason D. Huff ; Joel A. Ernster ; Gerald A. White ; Anuj V. PeddadaSource :
- Head & Neck [ 1043-3074 ] ; 2009-09.
English descriptors
- KwdEn :
- Actuarial rates, Acute toxicity, Biol, Carcinoma, Chemotherapy, Clin oncol, Colorado springs, Community cancer center, Community cancer centers, Community cancer experience, Concomitant, Concurrent chemoradiotherapy, Concurrent chemotherapy, Concurrent cisplatin, Contralateral parotid gland, Current series, Distant survival, Fractionation, Fractionation head, Fractionation imrt, Head september, Imrt, Induction chemotherapy, Ipsilateral nodal disease, Local control, Median, Medical oncology, Multiagent chemotherapy, Neck cancer, Neck imrt, Neck radiation therapy, Nodal, Oncol, Oncology, Outcome data, Overall survival, Parotid, Patient characteristics, Penrose cancer center, Phys, Prescription dose, Primary site, Primary tumor, Radiat, Radiat oncol biol phys, Radiation oncology, Radiation therapy, Radiotherapy, Recurrence, Regional control, Same time, September, Single patient, Spinal cord, Squamous cell carcinoma, Target delineation, Thermoplastic mask, Toxicity, Treatment planning, Univariate analysis, Weight loss, Wiley periodicals.
- Teeft :
- Actuarial rates, Acute toxicity, Biol, Carcinoma, Chemotherapy, Clin oncol, Colorado springs, Community cancer center, Community cancer centers, Community cancer experience, Concomitant, Concurrent chemoradiotherapy, Concurrent chemotherapy, Concurrent cisplatin, Contralateral parotid gland, Current series, Distant survival, Fractionation, Fractionation head, Fractionation imrt, Head september, Imrt, Induction chemotherapy, Ipsilateral nodal disease, Local control, Median, Medical oncology, Multiagent chemotherapy, Neck cancer, Neck imrt, Neck radiation therapy, Nodal, Oncol, Oncology, Outcome data, Overall survival, Parotid, Patient characteristics, Penrose cancer center, Phys, Prescription dose, Primary site, Primary tumor, Radiat, Radiat oncol biol phys, Radiation oncology, Radiation therapy, Radiotherapy, Recurrence, Regional control, Same time, September, Single patient, Spinal cord, Squamous cell carcinoma, Target delineation, Thermoplastic mask, Toxicity, Treatment planning, Univariate analysis, Weight loss, Wiley periodicals.
Abstract
This article reviews our community cancer center's experience treating head and neck cancer primarily with accelerated fractionation intensity‐modulated radiation therapy (IMRT), with or without concurrent chemotherapy, focusing on acute toxicity and efficacy.
Url:
DOI: 10.1002/hed.21078
Links to Exploration step
ISTEX:6EAD6CBF89CF47CE75B1EAE37B7F43716CA9EF17Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Accelerated fractionation head and neck intensity‐modulated radiation therapy and concurrent chemotherapy in the community setting: Safety and efficacy considerations</title><author><name sortKey="Monroe, Alan T" sort="Monroe, Alan T" uniqKey="Monroe A" first="Alan T." last="Monroe">Alan T. Monroe</name><affiliation><mods:affiliation>Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: dralmonroe@yahoo.com</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado</mods:affiliation></affiliation></author><author><name sortKey="Young, James A" sort="Young, James A" uniqKey="Young J" first="James A." last="Young">James A. Young</name><affiliation><mods:affiliation>Penrose Cancer Center, Department of Medical Oncology, Colorado Springs, Colorado</mods:affiliation></affiliation></author><author><name sortKey="Huff, Jason D" sort="Huff, Jason D" uniqKey="Huff J" first="Jason D." last="Huff">Jason D. Huff</name><affiliation><mods:affiliation>Penrose Cancer Center, Department of Medical Oncology, Colorado Springs, Colorado</mods:affiliation></affiliation></author><author><name sortKey="Ernster, Joel A" sort="Ernster, Joel A" uniqKey="Ernster J" first="Joel A." last="Ernster">Joel A. Ernster</name><affiliation><mods:affiliation>Colorado Otolaryngology Associates, Colorado Springs, Colorado</mods:affiliation></affiliation></author><author><name sortKey="White, Gerald A" sort="White, Gerald A" uniqKey="White G" first="Gerald A." last="White">Gerald A. White</name><affiliation><mods:affiliation>Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado</mods:affiliation></affiliation></author><author><name sortKey="Peddada, Anuj V" sort="Peddada, Anuj V" uniqKey="Peddada A" first="Anuj V." last="Peddada">Anuj V. Peddada</name><affiliation><mods:affiliation>Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6EAD6CBF89CF47CE75B1EAE37B7F43716CA9EF17</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/hed.21078</idno><idno type="url">https://api.istex.fr/document/6EAD6CBF89CF47CE75B1EAE37B7F43716CA9EF17/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003681</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">003681</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Accelerated fractionation head and neck intensity‐modulated radiation therapy and concurrent chemotherapy in the community setting: Safety and efficacy considerations</title><author><name sortKey="Monroe, Alan T" sort="Monroe, Alan T" uniqKey="Monroe A" first="Alan T." last="Monroe">Alan T. Monroe</name><affiliation><mods:affiliation>Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: dralmonroe@yahoo.com</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado</mods:affiliation></affiliation></author><author><name sortKey="Young, James A" sort="Young, James A" uniqKey="Young J" first="James A." last="Young">James A. Young</name><affiliation><mods:affiliation>Penrose Cancer Center, Department of Medical Oncology, Colorado Springs, Colorado</mods:affiliation></affiliation></author><author><name sortKey="Huff, Jason D" sort="Huff, Jason D" uniqKey="Huff J" first="Jason D." last="Huff">Jason D. Huff</name><affiliation><mods:affiliation>Penrose Cancer Center, Department of Medical Oncology, Colorado Springs, Colorado</mods:affiliation></affiliation></author><author><name sortKey="Ernster, Joel A" sort="Ernster, Joel A" uniqKey="Ernster J" first="Joel A." last="Ernster">Joel A. Ernster</name><affiliation><mods:affiliation>Colorado Otolaryngology Associates, Colorado Springs, Colorado</mods:affiliation></affiliation></author><author><name sortKey="White, Gerald A" sort="White, Gerald A" uniqKey="White G" first="Gerald A." last="White">Gerald A. White</name><affiliation><mods:affiliation>Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado</mods:affiliation></affiliation></author><author><name sortKey="Peddada, Anuj V" sort="Peddada, Anuj V" uniqKey="Peddada A" first="Anuj V." last="Peddada">Anuj V. Peddada</name><affiliation><mods:affiliation>Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Head & Neck</title><title level="j" type="alt">HEAD AND NECK</title><idno type="ISSN">1043-3074</idno><idno type="eISSN">1097-0347</idno><imprint><biblScope unit="vol">31</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1144">1144</biblScope><biblScope unit="page" to="1151">1151</biblScope><biblScope unit="page-count">8</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-09">2009-09</date></imprint><idno type="ISSN">1043-3074</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1043-3074</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Actuarial rates</term><term>Acute toxicity</term><term>Biol</term><term>Carcinoma</term><term>Chemotherapy</term><term>Clin oncol</term><term>Colorado springs</term><term>Community cancer center</term><term>Community cancer centers</term><term>Community cancer experience</term><term>Concomitant</term><term>Concurrent chemoradiotherapy</term><term>Concurrent chemotherapy</term><term>Concurrent cisplatin</term><term>Contralateral parotid gland</term><term>Current series</term><term>Distant survival</term><term>Fractionation</term><term>Fractionation head</term><term>Fractionation imrt</term><term>Head september</term><term>Imrt</term><term>Induction chemotherapy</term><term>Ipsilateral nodal disease</term><term>Local control</term><term>Median</term><term>Medical oncology</term><term>Multiagent chemotherapy</term><term>Neck cancer</term><term>Neck imrt</term><term>Neck radiation therapy</term><term>Nodal</term><term>Oncol</term><term>Oncology</term><term>Outcome data</term><term>Overall survival</term><term>Parotid</term><term>Patient characteristics</term><term>Penrose cancer center</term><term>Phys</term><term>Prescription dose</term><term>Primary site</term><term>Primary tumor</term><term>Radiat</term><term>Radiat oncol biol phys</term><term>Radiation oncology</term><term>Radiation therapy</term><term>Radiotherapy</term><term>Recurrence</term><term>Regional control</term><term>Same time</term><term>September</term><term>Single patient</term><term>Spinal cord</term><term>Squamous cell carcinoma</term><term>Target delineation</term><term>Thermoplastic mask</term><term>Toxicity</term><term>Treatment planning</term><term>Univariate analysis</term><term>Weight loss</term><term>Wiley periodicals</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Actuarial rates</term><term>Acute toxicity</term><term>Biol</term><term>Carcinoma</term><term>Chemotherapy</term><term>Clin oncol</term><term>Colorado springs</term><term>Community cancer center</term><term>Community cancer centers</term><term>Community cancer experience</term><term>Concomitant</term><term>Concurrent chemoradiotherapy</term><term>Concurrent chemotherapy</term><term>Concurrent cisplatin</term><term>Contralateral parotid gland</term><term>Current series</term><term>Distant survival</term><term>Fractionation</term><term>Fractionation head</term><term>Fractionation imrt</term><term>Head september</term><term>Imrt</term><term>Induction chemotherapy</term><term>Ipsilateral nodal disease</term><term>Local control</term><term>Median</term><term>Medical oncology</term><term>Multiagent chemotherapy</term><term>Neck cancer</term><term>Neck imrt</term><term>Neck radiation therapy</term><term>Nodal</term><term>Oncol</term><term>Oncology</term><term>Outcome data</term><term>Overall survival</term><term>Parotid</term><term>Patient characteristics</term><term>Penrose cancer center</term><term>Phys</term><term>Prescription dose</term><term>Primary site</term><term>Primary tumor</term><term>Radiat</term><term>Radiat oncol biol phys</term><term>Radiation oncology</term><term>Radiation therapy</term><term>Radiotherapy</term><term>Recurrence</term><term>Regional control</term><term>Same time</term><term>September</term><term>Single patient</term><term>Spinal cord</term><term>Squamous cell carcinoma</term><term>Target delineation</term><term>Thermoplastic mask</term><term>Toxicity</term><term>Treatment planning</term><term>Univariate analysis</term><term>Weight loss</term><term>Wiley periodicals</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">This article reviews our community cancer center's experience treating head and neck cancer primarily with accelerated fractionation intensity‐modulated radiation therapy (IMRT), with or without concurrent chemotherapy, focusing on acute toxicity and efficacy.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>imrt</json:string><json:string>chemotherapy</json:string><json:string>toxicity</json:string><json:string>concomitant</json:string><json:string>oncol</json:string><json:string>neck cancer</json:string><json:string>acute toxicity</json:string><json:string>concurrent chemotherapy</json:string><json:string>neck imrt</json:string><json:string>phys</json:string><json:string>biol</json:string><json:string>radiat</json:string><json:string>radiat oncol biol phys</json:string><json:string>oncology</json:string><json:string>september</json:string><json:string>nodal</json:string><json:string>radiotherapy</json:string><json:string>local control</json:string><json:string>parotid</json:string><json:string>head september</json:string><json:string>penrose cancer center</json:string><json:string>recurrence</json:string><json:string>median</json:string><json:string>distant survival</json:string><json:string>multiagent chemotherapy</json:string><json:string>regional control</json:string><json:string>univariate analysis</json:string><json:string>carcinoma</json:string><json:string>clin oncol</json:string><json:string>overall survival</json:string><json:string>radiation therapy</json:string><json:string>prescription dose</json:string><json:string>contralateral parotid gland</json:string><json:string>primary tumor</json:string><json:string>colorado springs</json:string><json:string>fractionation imrt</json:string><json:string>fractionation</json:string><json:string>primary site</json:string><json:string>thermoplastic mask</json:string><json:string>squamous cell carcinoma</json:string><json:string>target delineation</json:string><json:string>outcome data</json:string><json:string>spinal cord</json:string><json:string>ipsilateral nodal disease</json:string><json:string>fractionation head</json:string><json:string>treatment planning</json:string><json:string>community cancer centers</json:string><json:string>single patient</json:string><json:string>induction chemotherapy</json:string><json:string>patient characteristics</json:string><json:string>concurrent chemoradiotherapy</json:string><json:string>same time</json:string><json:string>weight loss</json:string><json:string>current series</json:string><json:string>community cancer center</json:string><json:string>wiley periodicals</json:string><json:string>actuarial rates</json:string><json:string>community cancer experience</json:string><json:string>medical oncology</json:string><json:string>radiation oncology</json:string><json:string>neck radiation therapy</json:string><json:string>concurrent cisplatin</json:string></teeft></keywords><author><json:item><name>Alan T. Monroe MD</name><affiliations><json:string>Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado</json:string><json:string>E-mail: dralmonroe@yahoo.com</json:string><json:string>Correspondence address: Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado</json:string></affiliations></json:item><json:item><name>James A. Young MD</name><affiliations><json:string>Penrose Cancer Center, Department of Medical Oncology, Colorado Springs, Colorado</json:string></affiliations></json:item><json:item><name>Jason D. Huff MD</name><affiliations><json:string>Penrose Cancer Center, Department of Medical Oncology, Colorado Springs, Colorado</json:string></affiliations></json:item><json:item><name>Joel A. Ernster MD</name><affiliations><json:string>Colorado Otolaryngology Associates, Colorado Springs, Colorado</json:string></affiliations></json:item><json:item><name>Gerald A. White MS</name><affiliations><json:string>Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado</json:string></affiliations></json:item><json:item><name>Anuj V. Peddada MD</name><affiliations><json:string>Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>IMRT</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>head and neck</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>accelerated fractionation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>community cancer center</value></json:item></subject><articleId><json:string>HED21078</json:string></articleId><arkIstex>ark:/67375/WNG-96B097Z8-T</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>This article reviews our community cancer center's experience treating head and neck cancer primarily with accelerated fractionation intensity‐modulated radiation therapy (IMRT), with or without concurrent chemotherapy, focusing on acute toxicity and efficacy.</abstract><qualityIndicators><refBibsNative>true</refBibsNative><abstractWordCount>32</abstractWordCount><abstractCharCount>260</abstractCharCount><keywordCount>4</keywordCount><score>6.144</score><pdfWordCount>3760</pdfWordCount><pdfCharCount>25042</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>8</pdfPageCount><pdfPageSize>612 x 810 pts</pdfPageSize></qualityIndicators><title>Accelerated fractionation head and neck intensity‐modulated radiation therapy and concurrent chemotherapy in the community setting: Safety and efficacy considerations</title><pmid><json:string>19340861</json:string></pmid><genre><json:string>article</json:string></genre><host><title>Head & Neck</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1097-0347</json:string></doi><issn><json:string>1043-3074</json:string></issn><eissn><json:string>1097-0347</json:string></eissn><publisherId><json:string>HED</json:string></publisherId><volume>31</volume><issue>9</issue><pages><first>1144</first><last>1151</last><total>8</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Original Article</value></json:item></subject></host><namedEntities><unitex><date><json:string>2009</json:string><json:string>5000</json:string><json:string>September 2009 1147</json:string><json:string>4000</json:string><json:string>September 2009 1144</json:string><json:string>September 2009 1149</json:string><json:string>2003</json:string><json:string>2600</json:string><json:string>6000</json:string><json:string>September 2009 1145</json:string><json:string>2004</json:string></date><geogName></geogName><orgName><json:string>Wiley Periodicals, Inc.</json:string><json:string>Penrose Cancer Center</json:string><json:string>Department of Medical Oncology, Colorado Springs, Colorado</json:string><json:string>SAS Institute, Cary, NC</json:string><json:string>El Paso, CO</json:string><json:string>University of Florida</json:string><json:string>Department of Radiation Oncology, Colorado Springs, Colorado</json:string><json:string>Wiley Periodicals, Inc</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Our</json:string><json:string>Jason D. Huff</json:string><json:string>A. White</json:string><json:string>Joel A. Ernster</json:string><json:string>A. T. Monroe</json:string><json:string>Anuj V. Peddada</json:string><json:string>James A. Young</json:string></persName><placeName><json:string>Bristol</json:string><json:string>Toxicity</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Brizel et al</json:string><json:string>Schoenfeld et al</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-96B097Z8-T</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - surgery</json:string><json:string>2 - otorhinolaryngology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - otorhinolaryngology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Otorhinolaryngology</json:string></scopus></categories><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/hed.21078</json:string></doi><id>6EAD6CBF89CF47CE75B1EAE37B7F43716CA9EF17</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/6EAD6CBF89CF47CE75B1EAE37B7F43716CA9EF17/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/6EAD6CBF89CF47CE75B1EAE37B7F43716CA9EF17/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/6EAD6CBF89CF47CE75B1EAE37B7F43716CA9EF17/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Accelerated fractionation head and neck intensity‐modulated radiation therapy and concurrent chemotherapy in the community setting: Safety and efficacy considerations</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><licence>Copyright © 2009 Wiley Periodicals, Inc.</licence></availability><date type="published" when="2009-09"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main" xml:lang="en">Accelerated fractionation head and neck intensity‐modulated radiation therapy and concurrent chemotherapy in the community setting: Safety and efficacy considerations</title><title level="a" type="short" xml:lang="en">Head and Neck IMRT in the Community Setting</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">Alan T.</forename><surname>Monroe</surname><roleName type="degree">MD</roleName></persName><email>dralmonroe@yahoo.com</email><affiliation>Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado<address><country key="US"></country></address></affiliation><affiliation>Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado</affiliation></author><author xml:id="author-0001"><persName><forename type="first">James A.</forename><surname>Young</surname><roleName type="degree">MD</roleName></persName><affiliation>Penrose Cancer Center, Department of Medical Oncology, Colorado Springs, Colorado<address><country key="US"></country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Jason D.</forename><surname>Huff</surname><roleName type="degree">MD</roleName></persName><affiliation>Penrose Cancer Center, Department of Medical Oncology, Colorado Springs, Colorado<address><country key="US"></country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Joel A.</forename><surname>Ernster</surname><roleName type="degree">MD</roleName></persName><affiliation>Colorado Otolaryngology Associates, Colorado Springs, Colorado<address><country key="US"></country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">Gerald A.</forename><surname>White</surname><roleName type="degree">MS</roleName></persName><affiliation>Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado<address><country key="US"></country></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">Anuj V.</forename><surname>Peddada</surname><roleName type="degree">MD</roleName></persName><affiliation>Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado<address><country key="US"></country></address></affiliation></author><idno type="istex">6EAD6CBF89CF47CE75B1EAE37B7F43716CA9EF17</idno><idno type="ark">ark:/67375/WNG-96B097Z8-T</idno><idno type="DOI">10.1002/hed.21078</idno><idno type="unit">HED21078</idno><idno type="toTypesetVersion">file:HED.HED21078.pdf</idno></analytic><monogr><title level="j" type="main">Head & Neck</title><title level="j" type="alt">HEAD AND NECK</title><idno type="pISSN">1043-3074</idno><idno type="eISSN">1097-0347</idno><idno type="book-DOI">10.1002/(ISSN)1097-0347</idno><idno type="book-part-DOI">10.1002/hed.v31:9</idno><idno type="product">HED</idno><imprint><biblScope unit="vol">31</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1144">1144</biblScope><biblScope unit="page" to="1151">1151</biblScope><biblScope unit="page-count">8</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-09"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head>
Background
<p>This article reviews our community cancer center's experience treating head and neck cancer primarily with accelerated fractionation intensity‐modulated radiation therapy (IMRT), with or without concurrent chemotherapy, focusing on acute toxicity and efficacy.</p>
Methods
<p>Fifty‐two patients treated with IMRT at the Penrose Cancer Center between 2002 and 2007 constitute the cohort. The majority (75%) received an accelerated, altered fractionation regimen, typically concomitant boost to 7200 cGy. Concurrent chemotherapy was delivered to 32 (62%). The median follow‐up was 24 months.</p>
Results
<p>The 2‐year actuarial rates of local control, regional control, and distant metastasis–free survival were 100%, 91%, and 94%, respectively. Relapse‐free survival and overall survival at 2 years were 89% and 91%, respectively. Overall, 32 of 52 patients (62%) experienced at least 1 type of grade 3 or 4 acute toxicity.</p>
Conclusion
<p>Accelerated fractionation IMRT, with or without chemotherapy, can be given safely and effectively in a community cancer center setting. © 2009 Wiley Periodicals, Inc. Head Neck, 2009</p></abstract><textClass><keywords xml:lang="en"><term xml:id="kwd1">IMRT</term><term xml:id="kwd2">head and neck</term><term xml:id="kwd3">accelerated fractionation</term><term xml:id="kwd4">community cancer center</term></keywords><keywords rend="articleCategory"><term>Original Article</term></keywords><keywords rend="tocHeading1"><term>Original Articles</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/6EAD6CBF89CF47CE75B1EAE37B7F43716CA9EF17/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1097-0347</doi><issn type="print">1043-3074</issn><issn type="electronic">1097-0347</issn><idGroup><id type="product" value="HED"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="HEAD AND NECK">Head & Neck</title><title type="subtitle">Journal for the Sciences and Specialties of the Head and Neck</title><title type="short">Head Neck</title></titleGroup></publicationMeta><publicationMeta level="part" position="90"><doi origin="wiley" registered="yes">10.1002/hed.v31:9</doi><numberingGroup><numbering type="journalVolume" number="31">31</numbering><numbering type="journalIssue">9</numbering></numberingGroup><coverDate startDate="2009-09">September 2009</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="40" status="forIssue"><doi origin="wiley" registered="yes">10.1002/hed.21078</doi><idGroup><id type="unit" value="HED21078"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Original Article</title><title type="tocHeading1">Original Articles</title></titleGroup><copyright ownership="publisher">Copyright © 2009 Wiley Periodicals, Inc.</copyright><eventGroup><event type="manuscriptAccepted" date="2008-10-31"></event><event type="publishedOnlineEarlyUnpaginated" date="2009-04-01"></event><event type="firstOnline" date="2009-04-01"></event><event type="publishedOnlineFinalForm" date="2009-08-07"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-06"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-27"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-24"></event></eventGroup><numberingGroup><numbering type="pageFirst">1144</numbering><numbering type="pageLast">1151</numbering></numberingGroup><correspondenceTo>Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:HED.HED21078.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="17"></count><count type="wordTotal" number="5055"></count></countGroup><titleGroup><title type="main" xml:lang="en">Accelerated fractionation head and neck intensity‐modulated radiation therapy and concurrent chemotherapy in the community setting: Safety and efficacy considerations</title><title type="short" xml:lang="en">Head and Neck IMRT in the Community Setting</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Alan T.</givenNames><familyName>Monroe</familyName><degrees>MD</degrees></personName><contactDetails><email>dralmonroe@yahoo.com</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>James A.</givenNames><familyName>Young</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Jason D.</givenNames><familyName>Huff</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Joel A.</givenNames><familyName>Ernster</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Gerald A.</givenNames><familyName>White</familyName><degrees>MS</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Anuj V.</givenNames><familyName>Peddada</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Penrose Cancer Center, Department of Medical Oncology, Colorado Springs, Colorado</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Colorado Otolaryngology Associates, Colorado Springs, Colorado</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">IMRT</keyword><keyword xml:id="kwd2">head and neck</keyword><keyword xml:id="kwd3">accelerated fractionation</keyword><keyword xml:id="kwd4">community cancer center</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><section xml:id="abs1-1"><title type="main">Background</title><p>This article reviews our community cancer center's experience treating head and neck cancer primarily with accelerated fractionation intensity‐modulated radiation therapy (IMRT), with or without concurrent chemotherapy, focusing on acute toxicity and efficacy.</p></section><section xml:id="abs1-2"><title type="main">Methods</title><p>Fifty‐two patients treated with IMRT at the Penrose Cancer Center between 2002 and 2007 constitute the cohort. The majority (75%) received an accelerated, altered fractionation regimen, typically concomitant boost to 7200 cGy. Concurrent chemotherapy was delivered to 32 (62%). The median follow‐up was 24 months.</p></section><section xml:id="abs1-3"><title type="main">Results</title><p>The 2‐year actuarial rates of local control, regional control, and distant metastasis–free survival were 100%, 91%, and 94%, respectively. Relapse‐free survival and overall survival at 2 years were 89% and 91%, respectively. Overall, 32 of 52 patients (62%) experienced at least 1 type of grade 3 or 4 acute toxicity.</p></section><section xml:id="abs1-4"><title type="main">Conclusion</title><p>Accelerated fractionation IMRT, with or without chemotherapy, can be given safely and effectively in a community cancer center setting. © 2009 Wiley Periodicals, Inc. Head Neck, 2009</p></section></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Accelerated fractionation head and neck intensity‐modulated radiation therapy and concurrent chemotherapy in the community setting: Safety and efficacy considerations</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Head and Neck IMRT in the Community Setting</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Accelerated fractionation head and neck intensity‐modulated radiation therapy and concurrent chemotherapy in the community setting: Safety and efficacy considerations</title></titleInfo><name type="personal"><namePart type="given">Alan T.</namePart><namePart type="family">Monroe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado</affiliation><affiliation>E-mail: dralmonroe@yahoo.com</affiliation><affiliation>Correspondence address: Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">James A.</namePart><namePart type="family">Young</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Penrose Cancer Center, Department of Medical Oncology, Colorado Springs, Colorado</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jason D.</namePart><namePart type="family">Huff</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Penrose Cancer Center, Department of Medical Oncology, Colorado Springs, Colorado</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Joel A.</namePart><namePart type="family">Ernster</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Colorado Otolaryngology Associates, Colorado Springs, Colorado</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gerald A.</namePart><namePart type="family">White</namePart><namePart type="termsOfAddress">MS</namePart><affiliation>Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anuj V.</namePart><namePart type="family">Peddada</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Penrose Cancer Center, Department of Radiation Oncology, Colorado Springs, Colorado</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2009-09</dateIssued><dateValid encoding="w3cdtf">2008-10-31</dateValid><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">3</extent><extent unit="tables">3</extent><extent unit="references">17</extent><extent unit="words">5055</extent></physicalDescription><abstract>This article reviews our community cancer center's experience treating head and neck cancer primarily with accelerated fractionation intensity‐modulated radiation therapy (IMRT), with or without concurrent chemotherapy, focusing on acute toxicity and efficacy.</abstract><abstract>Fifty‐two patients treated with IMRT at the Penrose Cancer Center between 2002 and 2007 constitute the cohort. The majority (75%) received an accelerated, altered fractionation regimen, typically concomitant boost to 7200 cGy. Concurrent chemotherapy was delivered to 32 (62%). The median follow‐up was 24 months.</abstract><abstract>The 2‐year actuarial rates of local control, regional control, and distant metastasis–free survival were 100%, 91%, and 94%, respectively. Relapse‐free survival and overall survival at 2 years were 89% and 91%, respectively. Overall, 32 of 52 patients (62%) experienced at least 1 type of grade 3 or 4 acute toxicity.</abstract><abstract>Accelerated fractionation IMRT, with or without chemotherapy, can be given safely and effectively in a community cancer center setting. © 2009 Wiley Periodicals, Inc. Head Neck, 2009</abstract><subject lang="en"><genre>keywords</genre><topic>IMRT</topic><topic>head and neck</topic><topic>accelerated fractionation</topic><topic>community cancer center</topic></subject><relatedItem type="host"><titleInfo><title>Head & Neck</title><subTitle>Journal for the Sciences and Specialties of the Head and Neck</subTitle></titleInfo><titleInfo type="abbreviated"><title>Head Neck</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Original Article</topic></subject><identifier type="ISSN">1043-3074</identifier><identifier type="eISSN">1097-0347</identifier><identifier type="DOI">10.1002/(ISSN)1097-0347</identifier><identifier type="PublisherID">HED</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><detail type="issue"><caption>no.</caption><number>9</number></detail><extent unit="pages"><start>1144</start><end>1151</end><total>8</total></extent></part></relatedItem><identifier type="istex">6EAD6CBF89CF47CE75B1EAE37B7F43716CA9EF17</identifier><identifier type="ark">ark:/67375/WNG-96B097Z8-T</identifier><identifier type="DOI">10.1002/hed.21078</identifier><identifier type="ArticleID">HED21078</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Wiley Periodicals, Inc.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/document/6EAD6CBF89CF47CE75B1EAE37B7F43716CA9EF17/metadata/json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/EdenteV2/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003681 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003681 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= EdenteV2
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:6EAD6CBF89CF47CE75B1EAE37B7F43716CA9EF17
|texte= Accelerated fractionation head and neck intensity‐modulated radiation therapy and concurrent chemotherapy in the community setting: Safety and efficacy considerations
}}
| This area was generated with Dilib version V0.6.32. |  |